New HIV Vaccine Development Opportunity to explore collaboration for the development of an HIV vaccine candidate leveraging Aridis Pharmaceuticals' broadly neutralizing antibody platform, presenting a potential sales avenue to offer support in this groundbreaking initiative.

Investment from CFF With a significant investment of $4.85 million from the Cystic Fibrosis Foundation, Aridis Pharmaceuticals is actively advancing AR-501 nebulized gallium citrate for treating chronic lung infections, highlighting an area where sales strategies can align with ongoing funding and research efforts.

Grant for Inhaled Formulation Technology The $1.9 million grant received from the Gates Foundation for evaluating inhaled formulation technology to deliver monoclonal antibodies against influenza and SARS-CoV-2 signifies a focus on global healthcare solutions, offering a potential sales opportunity in supporting this innovative approach.

Strategic Partnership with UAB and Texas Biomed Collaboration with partners like UAB and Texas Biomed to develop inhaled antibody treatments presents a strategic avenue for sales expansion, tapping into the momentum of successful antibody candidates deployment akin to asthma inhalers.

Exclusive Licensing Agreement with AstraZeneca The exclusive worldwide licensing agreement with AstraZeneca for suvratoxumab, a late-stage monoclonal antibody candidate, opens up avenues for sales collaboration and business development in the realm of advanced anti-infectives, marking a significant opportunity for revenue growth.